Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease

• Published in: Journal of Crohn's and colitis Vol. 6; no. 10; pp. 1034 - 1037
• Main Authors: Casanova, M.J., Chaparro, M., Martínez, S., Vicuña, I., Gisbert, J.P.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01-12-2012
• Subjects: Adalimumab; Aged; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Crohn Disease - drug therapy; Crohn's disease; Female; Humans; Thrombocytopenia; Thrombocytopenia - chemically induced; Thrombocytopenia - therapy; Thrombocytopenia; CD; TNF-α; IVIG; IBD; Crohn's disease; Adalimumab
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1016/j.crohns.2012.04.001

Crohn's disease is a chronic transmural inflammatory disorder characterized by inflammation of the intestine. Anti-TNF-α drugs are used for induction and maintenance of remission in patients with this condition. Thrombocytopenia is an uncommon side effect of treatment with anti-TNF-α drugs. We report the case of a 71-year-old woman diagnosed with Crohn's disease who developed severe adalimumab-induced thrombocytopenia and who did not respond to standard therapy for thrombocytopenia.